Nestle now has less than two weeks to convince the regulator why product approval for its noodles should not be withdrawn
Pharma major Ranbaxy Laboratories has set aside Rs 257.4 crore (Rs 2.57 billion) towards the financial impact of a US ban on import of products made at its plant at Toansa.
Sun Pharma profit down 30% over compliance costs, lower sales.
IT, pharma and FMCG stocks are the top performers in 2013.
The company spokesperson expressed disappointment with the "unprecedented step of filing of a complaint before the NCDRC"
While the US health regulator did not specify details for issuing the alert, it said 'detention without physical examination may be appropriate when an FDA inspection has revealed that a firm is not operating in conformity with current good manufacturing practices'.
.jpg)
The report comes at a time when the government is trying to clear pending FDI proposals, which include various planned investments in this sector.
While Reliance Retail did not comment, sources said the company will have to follow order, at least in Delhi.
The combined sales of the branded versions of the products in the US is about $3.5 billion.
According to Munjal, there is an opportunity for somebody who comes from a not for profit background in health care to do something.
market, was today seized from an illegal drug manufacturing unit in Jalgaon district in north Maharashtra and six persons were arrested, Directorate of Revenue Intelligence officials said.
DRL launched four new products in North America during the previous quarter.
In India, thousands of lives are lost every year because of unavailability of organs
4 Ranbaxy facilities in India have been barred from exporting to US.
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
A look at the top tweets from your favourite Bollywood celebrities.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
Lack of clarity on whether manufacturing bans in Punjab, Uttarakhand, Himachal, Goa and Karnataka still in place
'India easily remains one among the more attractive large economies, with high growth and stable/improving macros, as a top investment destination.' 'We are looking pretty good.'
Sun Pharma's offer was tempting because Ranbaxy was too busy fighting fires in the US to concentrate on operations.
Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.
'The mismatch between valuations and fundamentals is startling,' warns Devangshu Datta
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
With global markets pushing ahead, enthused by strengthening US jobs market, and also due to prospects of European rate hike, Indian markets also continued the march ahead.
The US Drug maker requested the court to pass an order to restrain DRL from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing DRL's generic paricalcitol injectable products prior to the expiration of said patents.
It was a disturbing message in the sense that the regulatory framework is not clear enough and is not always applied in a convincing manner.
Aneesh Phadnis and Veena Mani find out what the manufacturers and the hospitals have to say.
.jpg)
Markets ended flat on Tuesday, amid a volatile trading session, as investors exercised caution ahead of the two-day FOMC meet starting today and Reserve Bank of India's monetary policy later this week.
Rate sensitive sectors were among the top gainers with Tata Motors and ICICI Bank leading the gains on the Sensex.
The past eight months have seen vast improvement in the Indian economy, says Edelweiss Group chairman and chief executive Rashesh Shah, who feels domestic-oriented sectors are likely to do better.
Markets ended their lowest close in 2015 on fears of FII outflows as the US Fed may hike rates.
A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.
Conor McGregor said on Tuesday he was retiring from the sport, five months after losing to Khabib Nurmagomedov in a controversial title fight
The S&P BSE Sensex closed 318 points at 24,455 and the Nifty50 shed 99 points to end at 7,438.
Another year of strong performance by these export-oriented sectors likely as US economy revives and rupee is expected to be under pressure.
Prosecutors unveiled charges against Valvani alleging he fraudulently made $25 million by getting advance information about US Food and Drug Administration approvals of generic drug applications
According to market experts, GST Bill, movement of the rupee and uncertain global cues amid expected rate cut by the US Fed will dictate the movement of the markets.
Popular antacid Mucaine Gel, manufactured by Pfizer's subsidiary Wyeth Laboratories, was also found laced with the heavy metals as well as cadmium.
Maggi re-entered the market on November 9.
